Literature DB >> 32865967

Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.

Chelsea E Powell1,2, Guangyan Du1,2, Jianwei Che1,2, Zhixiang He1,2, Katherine A Donovan1,2, Hong Yue1,2, Eric S Wang1,2, Radosław P Nowak1,2, Tinghu Zhang1,2, Eric S Fischer1,2, Nathanael S Gray1,2.   

Abstract

Cereblon (CRBN) is an E3 ligase adapter protein that can be reprogrammed by imide-class compounds such as thalidomide, lenalidomide, and pomalidomide to induce the degradation of neo-substrate proteins. In order to identify additional small molecule CRBN modulators, we implemented a focused combinatorial library approach where we fused an imide-based CRBN-binding pharmacophore to a heterocyclic scaffold, which could be further elaborated. We screened the library for CRBN-dependent antiproliferative activity in the multiple myeloma cell line MM1.S and identified five hit compounds. Quantitative chemical proteomics of hit compounds revealed that they induced selective degradation of GSPT1, a translation termination factor that is currently being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular docking studies with CRBN and GSPT1 followed by analogue synthesis identified a possible hydrogen bond interaction with the central pyrimidine ring as a molecular determinant of hit compounds' selectivity. This study demonstrates that a focused combinatorial library design, phenotypic screening, and chemical proteomics can provide a suitable workflow to efficiently identify novel CRBN modulators.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32865967      PMCID: PMC7843009          DOI: 10.1021/acschembio.0c00520

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  31 in total

Review 1.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.

Authors:  Georg Petzold; Eric S Fischer; Nicolas H Thomä
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

Review 3.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

4.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

5.  Mouse GSPT2, but not GSPT1, can substitute for yeast eRF3 in vivo.

Authors:  Catherine Le Goff; Olga Zemlyanko; Svetlana Moskalenko; Nadia Berkova; Sergei Inge-Vechtomov; Michel Philippe; Galina Zhouravleva
Journal:  Genes Cells       Date:  2002-10       Impact factor: 1.891

6.  Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Authors:  Philip P Chamberlain; Antonia Lopez-Girona; Karen Miller; Gilles Carmel; Barbra Pagarigan; Barbara Chie-Leon; Emily Rychak; Laura G Corral; Yan J Ren; Maria Wang; Mariko Riley; Silvia L Delker; Takumi Ito; Hideki Ando; Tomoyuki Mori; Yoshinori Hirano; Hiroshi Handa; Toshio Hakoshima; Thomas O Daniel; Brian E Cathers
Journal:  Nat Struct Mol Biol       Date:  2014-08-10       Impact factor: 15.369

7.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors:  A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

8.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

9.  Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.

Authors:  Katherine A Donovan; Jian An; Radosław P Nowak; Jingting C Yuan; Emma C Fink; Bethany C Berry; Benjamin L Ebert; Eric S Fischer
Journal:  Elife       Date:  2018-08-01       Impact factor: 8.140

10.  Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML.

Authors:  Matthias Brand; Baishan Jiang; Sophie Bauer; Katherine A Donovan; Yanke Liang; Eric S Wang; Radosław P Nowak; Jingting C Yuan; Tinghu Zhang; Nicholas Kwiatkowski; André C Müller; Eric S Fischer; Nathanael S Gray; Georg E Winter
Journal:  Cell Chem Biol       Date:  2018-12-27       Impact factor: 9.039

View more
  7 in total

1.  Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay.

Authors:  Wenwei Lin; Yongtao Li; Jaeki Min; Jiuyu Liu; Lei Yang; Richard E Lee; Taosheng Chen
Journal:  Bioconjug Chem       Date:  2020-10-18       Impact factor: 4.774

2.  CRISPR-Suppressor Scanning Unsticks Molecular Glues.

Authors:  Stephanie A Robinson; Steven M Banik
Journal:  ACS Cent Sci       Date:  2022-03-08       Impact factor: 18.728

3.  Ligandability of E3 Ligases for Targeted Protein Degradation Applications.

Authors:  Bridget P Belcher; Carl C Ward; Daniel K Nomura
Journal:  Biochemistry       Date:  2021-09-02       Impact factor: 3.162

4.  Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.

Authors:  Bo Wang; Jin Liu; Ira Tandon; Suzhen Wu; Peng Teng; Jianhua Liao; Weiping Tang
Journal:  Eur J Med Chem       Date:  2021-04-04       Impact factor: 7.088

5.  Site-Specific Labeling of Endogenous Proteins Using CoLDR Chemistry.

Authors:  Rambabu N Reddi; Adi Rogel; Efrat Resnick; Ronen Gabizon; Pragati Kishore Prasad; Neta Gurwicz; Haim Barr; Ziv Shulman; Nir London
Journal:  J Am Chem Soc       Date:  2021-11-24       Impact factor: 15.419

6.  Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders.

Authors:  Pallavi M Gosavi; Kevin C Ngan; Megan J R Yeo; Cindy Su; Jiaming Li; Nicholas Z Lue; Samuel M Hoenig; Brian B Liau
Journal:  ACS Cent Sci       Date:  2022-02-14       Impact factor: 18.728

7.  SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics.

Authors:  Fernando J Sialana; Theodoros I Roumeliotis; Habib Bouguenina; Laura Chan Wah Hak; Hannah Wang; John Caldwell; Ian Collins; Rajesh Chopra; Jyoti S Choudhary
Journal:  J Proteome Res       Date:  2022-07-18       Impact factor: 5.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.